Loading clinical trials...
Loading clinical trials...
A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
Conditions
Interventions
migalastat HCl 150 mg
Locations
6
United States
University of South Florida
Tampa, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
University of Minnesota Masonic Children's Hospital and Clinics
Minneapolis, Minnesota, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Lysosomal & Rare Disorders Research & Treatment Center
Fairfax, Virginia, United States
Royal Free London NHS Foundation Trust
London, United Kingdom
Start Date
October 11, 2019
Primary Completion Date
November 29, 2024
Completion Date
November 29, 2024
Last Updated
February 5, 2026
NCT06941025
NCT07382128
NCT05923788
NCT05473637
NCT07277361
NCT04252066
Lead Sponsor
Amicus Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions